These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 29208625)

  • 1. Lowering Expectations with Niacin Treatment for CKD-MBD.
    Drüeke TB; Massy ZA
    Clin J Am Soc Nephrol; 2018 Jan; 13(1):6-8. PubMed ID: 29208625
    [No Abstract]   [Full Text] [Related]  

  • 2. Niacin and Chronic Kidney Disease.
    Taketani Y; Masuda M; Yamanaka-Okumura H; Tatsumi S; Segawa H; Miyamoto K; Takeda E; Yamamoto H
    J Nutr Sci Vitaminol (Tokyo); 2015; 61 Suppl():S173-5. PubMed ID: 26598845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nicotinamide and phosphate homeostasis in chronic kidney disease.
    Ginsberg C; Ix JH
    Curr Opin Nephrol Hypertens; 2016 Jul; 25(4):285-91. PubMed ID: 27219041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EOS789, a novel pan-phosphate transporter inhibitor, is effective for the treatment of chronic kidney disease-mineral bone disorder.
    Tsuboi Y; Ohtomo S; Ichida Y; Hagita H; Ozawa K; Iida M; Nagao S; Ikegami H; Takahashi T; Horiba N
    Kidney Int; 2020 Aug; 98(2):343-354. PubMed ID: 32624180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Effect of Extended Release Niacin on Markers of Mineral Metabolism in CKD.
    Malhotra R; Katz R; Hoofnagle A; Bostom A; Rifkin DE; Mcbride R; Probstfield J; Block G; Ix JH
    Clin J Am Soc Nephrol; 2018 Jan; 13(1):36-44. PubMed ID: 29208626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Derangements in phosphate metabolism in chronic kidney diseases/endstage renal disease: therapeutic considerations.
    Molony DA; Stephens BW
    Adv Chronic Kidney Dis; 2011 Mar; 18(2):120-31. PubMed ID: 21406297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).
    Isakova T; Nickolas TL; Denburg M; Yarlagadda S; Weiner DE; Gutiérrez OM; Bansal V; Rosas SE; Nigwekar S; Yee J; Kramer H
    Am J Kidney Dis; 2017 Dec; 70(6):737-751. PubMed ID: 28941764
    [TBL] [Abstract][Full Text] [Related]  

  • 8. To what extent can we achieve mineral bone metabolism treatment targets suggested by the KDIGO guidelines among chronic kidney disease stage 3 - 5 non-dialysis patients?
    Dincer MT; Ozcan SG; Alagoz S; Karaca C; Gulcicek SH; Trabulus S; Pekpak M; Seyahi N
    Clin Nephrol; 2022 Nov; 98(5):239-246. PubMed ID: 35979902
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of phosphorus load in CKD patients.
    Taketani Y; Koiwa F; Yokoyama K
    Clin Exp Nephrol; 2017 Mar; 21(Suppl 1):27-36. PubMed ID: 27896453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mineral Bone Disorders in Kidney Disease Patients: The Ever-Current Topic.
    Hu L; Napoletano A; Provenzano M; Garofalo C; Bini C; Comai G; La Manna G
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293076
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of Chronic Kidney Disease (CKD)-Mineral and Bone Disorder (MBD) in the Pathogenesis of Cardiovascular Disease in CKD.
    Yamada S; Nakano T
    J Atheroscler Thromb; 2023 Aug; 30(8):835-850. PubMed ID: 37258233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Chronic kidney disease--mineral and bone disorder: why and how to control phosphate].
    Pavlović D; Katicić D; Josipović J
    Acta Med Croatica; 2012 Oct; 66 Suppl 2():64-7. PubMed ID: 23513419
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Importance of Phosphate Control in Chronic Kidney Disease.
    Tsuchiya K; Akihisa T
    Nutrients; 2021 May; 13(5):. PubMed ID: 34069053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is chronic kidney disease-mineral bone disorder (CKD-MBD) really a syndrome?
    Cozzolino M; Ureña-Torres P; Vervloet MG; Brandenburg V; Bover J; Goldsmith D; Larsson TE; Massy ZA; Mazzaferro S;
    Nephrol Dial Transplant; 2014 Oct; 29(10):1815-20. PubMed ID: 24516228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperphosphatemia and Chronic Kidney Disease: A Major Daily Concern Both in Adults and in Children.
    Bacchetta J; Bernardor J; Garnier C; Naud C; Ranchin B
    Calcif Tissue Int; 2021 Jan; 108(1):116-127. PubMed ID: 31996964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pediatric CKD-MBD: existing and emerging treatment approaches.
    Ayoob RM; Mahan JD
    Pediatr Nephrol; 2022 Nov; 37(11):2599-2614. PubMed ID: 35038008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circadian rhythms of mineral metabolism in chronic kidney disease-mineral bone disorder.
    Egstrand S; Olgaard K; Lewin E
    Curr Opin Nephrol Hypertens; 2020 Jul; 29(4):367-377. PubMed ID: 32452917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mineral and Bone Disorder and Its Association with Cardiovascular Parameters in Chinese Patients with Chronic Kidney Disease.
    Zhou C; Wang F; Wang JW; Zhang LX; Zhao MH
    Chin Med J (Engl); 2016 Oct; 129(19):2275-80. PubMed ID: 27647184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphate binders in moderate chronic kidney disease: where do we stand?
    Bellasi A; Cozzolino M; Adragao T; Di Iorio B; Russo D
    J Nephrol; 2013; 26(6):993-1000. PubMed ID: 23543481
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiovascular risk in chronic kidney disease (CKD): the CKD-mineral bone disorder (CKD-MBD).
    Hruska KA; Choi ET; Memon I; Davis TK; Mathew S
    Pediatr Nephrol; 2010 Apr; 25(4):769-78. PubMed ID: 19898875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.